NS Pharma is a biopharmaceutical leader in delivering life-changing care to people living with complex, rare diseases, backed by over 100 years
of Nippon Shinyaku development expertise.
We are leaders at the forefront of transformative scientific discovery, steadfast in our long-term commitment to shepherding therapeutic advances into novel treatments that profoundly improve the lives of rare disease patients.
NS Pharma is advancing revolutionary rare disease therapies that address unmet needs for patients facing debilitating genetic conditions, such as Duchenne muscular dystrophy, Hunter syndrome, and Eosinophilic granulomatosis with polyangiitis (EGPA).
By uniting strategic partnerships, novel scientific innovation, and expansive organizational expertise, we consistently drive meaningful therapeutic progress for patients by investigating exon-skipping, gene therapy, cell therapy, and JAK1 inhibition technologies.
